Table 1

Demographic and clinical characteristics in accordance with cluster assignment

Cluster 1
(n=164)
Cluster 2
(n=66)
Cluster 3
(n=45)
Cluster 4
(n=91)
P value
Age, mean±SD (95% CI), years79.6±5.96
(78.7 to 80.5) (4)
78.1±6.91
(76.4 to 79.8) (4)
79.8±8.73
(77.2 to 82.5)
81.3±6.73
(79.8 to 82.7) (1,2)
0.0068
Women, n (%)72 (43.9%)28 (42.2%)19 (42.2%)27 (29.7%)0.1483
BMI, mean±SD (95% CI), kg/m226.3±4.39
(25.6 to 27.0)
27.6±3.96
(26.6 to 28.6)
26.7±4.43
(25.4 to 28.0)
27.1±4.83
(26.1 to 28.1)
0.1539
Arterial hypertension, n (%)141 (86.0%)62 (93.9%)45 (100%)86 (94.5%)0.0095
Diabetes mellitus, n (%)41 (25.0%)16 (24.2%)11 (24.4%)33 (36.3%)0.2127
NYHA functional class, mean±SD (95% CI)2.48±0.713
(2.37 to 2.59) (3,4)
2.52±0.662
(2.35 to 2.68) (3,4)
3.02±0.723
(2.81 to 3.24) (1,2)
2.87±0.778
(2.71 to 3.03) (1,2)
5.4×10–7
NYHA functional class III79 (48.2%)34 (51.5%)25 (55.6%)55 (60.4%)0.2932
NYHA functional class IV7 (4.27%) (3,4)2 (3.03%) (3,4)11 (24.4%) (1,2)15 (16.5%) (1,2)2.0×10–5
EuroSCORE, mean±SD (95% CI), %13.7±10.1
(12.2 to 15.3) (3,4)
13.9±11.2
(11.2 to 16.7) (3,4)
29.1±20.9
(22.8 to 35.4) (1,2)
22.6±14.6
(19.6 to 25.6) (1,2)
8.6×10–10
eGFR, mean±SD (95% CI), mL/min63.0±20.5
(59.8 to 66.2) (3,4)
64.6±21.6
(59.3 to 69.9) (3)
52.8±21.1
(46.4 to 59.1) (1,2)
56.0±19.9
(51.9 to 60.2) (1)
0.0046
CAD, n (%)137 (83.5%)58 (87.9%)36 (80.0%)80 (87.9%)0.5635
COPD, n (%)14 (8.54%) (3)10 (15.2%)11 (24.4%) (1)14 (15.4%)0.0376
Atrial fibrillation and/or flutter, n (%)33 (20.1%) (2,3,4)25 (37.9%) (1,3,4)34 (75.6%) (1,2)69 (75.8%) (1,2)<2.2×10-16
  • χ2 or Fisher’s exact test were used to evaluate the association between categorical variables, and Kruskal-Wallis test in combination with pairwise Wilcoxon test with correction for multiple testing (Benjamini-Hochberg method) was used for comparison of continuous variables, as appropriate. Numbers in parentheses indicate between which clusters significant differences (p value ≤0.05) were detected.

  • BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.